Highlights Ultimovacs ASA

Equities

ULTI

NO0010851603

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-04-30 am EDT			5-day change	1st Jan Change
6.98 ^NOK	+0.29%		-11.65%	-94.32%

Apr. 17	Ultimovacs to Reduce 40% of Workforce Amid Operational Adjustments	MT
Apr. 17	Transcript : Ultimovacs ASA - Special Call

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ultimovacs ASA Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program	Apr. 16	CI
Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma	Mar. 07	CI
Ultimovacs Wins Orphan Drug Designation in Europe for Cancer Vaccine	Feb. 19	MT
Ultimovacs ASA Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 14	CI
Ultimovacs ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 14	CI
Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma	Feb. 05	CI
Ultimovacs ASA Updates Timeline for Reporting on Randomized UV1 Phase II Trial Initium in Malignant Melanoma	Jan. 16	CI
Ultimovacs ASA Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint	Dec. 18	CI
Ultimovacs ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Ultimovacs ASA Announces Completion of Patient Enrollment in Supplementary Study to INITium, UV1 Phase II Trial in Malignant Melanoma	Nov. 02	CI
Ultimovacs ASA Announces Protocol Amendment in UV1 Phase II Study INITIUM in Malignant Melanoma, Enabling Data Readout in First Half of 2024	23-10-31	CI
Ultimovacs ASA Announces Full Dataset from the NIPU Clinical Trial (Nct04300244) Presented At the ESMO Congress 2023 in Madrid	23-10-23	CI
Ultimovacs ASA Announces the Results from the NIPU clinical trial (NCT04300244)	23-10-17	CI
Ultimovacs Provides 4-Year Update from Phase I Study in Malignant Melanoma: Demonstrating Sustained Long-Term Overall Survival in Patients Treated with Uv1 Cancer Vaccine	23-10-12	CI
Ultimovacs ASA Receives FDA Orphan Drug Designation for the Uv1 Cancer Vaccine for Treatment of Mesothelioma	23-10-09	CI
Ultimovacs ASA Announces the Results from Uv1 Phase Ii Clinical Trial Nipu in Malignant Mesothelioma Will Be Presented At the Esmo Congress 2023	23-09-27	CI
Ultimovacs ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-22	CI
Ultimovacs Announces Completed Enrollment in FOCUS Phase II Clinical Trial of UV1 in Head and Neck Cancer Patients	23-08-03	CI
Ultimovacs ASA Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results	23-06-28	CI
Ultimovacs Provides 3-Year Update from Phase I Study in Malignant Melanoma: Results Confirm Strong Overall Survival in Patients Treated with UV1 Cancer Vaccine	23-06-19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ultimovacs ASA

Equities

ULTI

NO0010851603

Highlights

Filters